Receptor Tyrosine Kinases as Targets for Anticancer Therapeutics

Authors: Carlomagno, Francesca1; Santoro, Massimo1

Source: Current Medicinal Chemistry, Volume 12, Number 15, July 2005 , pp. 1773-1781(9)

Publisher: Bentham Science Publishers

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Oncogenic conversion of receptor protein tyrosine kinases (RTK) is a frequent feature of malignant cells. This knowledge has fostered efforts to develop target-specific low molecular weight therapeutics able to obstruct RTK signalling. The clinical efficacy of the ABL- and KIT-inhibitors are paradigmatic of the power of this approach. Here, we focus on small-molecule inhibitors for RTKs involved in human cancer. In particular, we examine the KIT, MET and RET receptors that are targeted by genetic alterations in both sporadic and familial human tumours.

Keywords: kinase; tyrosine; oncogene; germline; thyroid; kit; met; ret

Document Type: Review article

DOI: 10.2174/0929867054367266

Affiliations: 1: Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita' di Napoli “Federico II”, via S. Pansini 5, 80131 Napoli, Italy.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A